US Vaccine Panel Retreats from mRNA Covid Review Ahead of Midterms
A major federal panel advising the US government on vaccines has retreated from efforts targeting Covid-19 mRNA vaccines, a shift that sources link to Republican worries about political fallout in the upcoming midterm elections. Several vaccine advisers selected by Health Secretary Robert F Kennedy Jr had been exploring the possibility of ending federal recommendations for mRNA Covid shots, but that initiative is no longer proceeding, according to two sources familiar with the discussions who spoke to the Washington Post.
Political and Safety Concerns Drive Retreat
Members of the health department's vaccine advisory committee, known as ACIP, have openly raised concerns in recent months about the safety and production of the vaccines, despite widespread research supporting their efficacy. Some comments included repeating debunked claims about DNA contamination in the shots posing health risks. The move away from direct criticism comes as Republicans face plummeting polling numbers ahead of the November midterm elections, alongside continuous criticism from medical professionals.
In a statement to the Guardian, Emily G Hilliard, press secretary for the US Department of Health and Human Services, clarified that the committee has not reconsidered its September 2025 decision to classify Covid vaccines under shared clinical decision-making on CDC immunization schedules. She emphasized alignment between the FDA and ACIP, noting that FDA approval for high-risk groups and ACIP recommendations are compatible, with vaccination decisions based on individual patient characteristics.
Expert Analysis on Committee's Role
Dorit Reiss, a vaccine law expert and professor at UC Law San Francisco, explained that the retreat reflects two key factors. First, the administration aims to avoid creating more controversy around vaccines, recognizing the political harm as most voters do not support Kennedy's anti-vaccine agenda. Second, the current ACIP members may not fully understand their role, which does not extend to setting insurance codes or creating anti-vaccine propaganda. Reiss noted that had ACIP voted on Covid-19 vaccines without proper notice, it would have violated the Federal Advisory Committee Act, making such actions legally vulnerable.
Reiss further criticized the committee's focus, stating that including Covid-19 vaccine injury and long Covid in discussions is strange, as ACIP's role is to make evidence-based vaccine recommendations, not treat diseases or promote claims about vaccine harms. The two mRNA vaccines currently used in the US, produced by Moderna and the Pfizer-BioNTech partnership, account for the vast majority of Covid-19 vaccinations administered.
Broader Context and Recent Developments
This retreat aligns with a quieter shift from the Trump administration's earlier stance that immunizations pose a significant threat to public health. Last week, it was announced that Vinay Prasad, the top vaccine official at the FDA, would depart again following controversies involving the agency's vaccine reviews, marking his second exit in under a year. Additionally, last month, Casey Means, Trump's controversial nominee for US surgeon general, sidestepped direct questions on vaccine guidance during a Senate health committee hearing, acknowledging overwhelming evidence refuting links between vaccines and autism while emphasizing that science is never settled.
The FDA also recently reversed an earlier decision and agreed to evaluate Moderna's application for what would be the first mRNA-based flu vaccine, after previously declining to review it. These developments highlight ongoing tensions between political pressures, public health guidance, and the evolving role of advisory committees in shaping US vaccine policy.
